ResMed (RMD) Stock Trades Down, Here Is Why

robot
Abstract generation in progress

Shares of medical device company ResMed (RMD) fell 2.6% after its Chairman and CEO, Michael J. Farrell, sold $1.25 million worth of shares. This insider selling, even if pre-arranged, raised investor concerns, while analysts at Baird also lowered their price target for the stock to $272 from $281, maintaining a Neutral rating. Despite its low volatility, the market sees this news as significant.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin